LUGANO-MADRID, 11 September, 2017 - The debate on whether to shorten adjuvant chemotherapy for colon cancer from six to three months takes centre stage today in a special session at the ESMO 2017 Congress in Madrid. (1)
Is three months of chemotherapy enough in the adjuvant treatment of colon cancer? This is the main controversy in this debate, according to ESMO spokesperson Professor Alberto Sobrero, Head of the Medical Oncology Unit at Ospedale San Martino in Genova, Italy, co-chair of the Special Session and Scientific Co-Chair of the Congress. He said: "This debate is a practice changing one and the session will give much more clarity on how clinicians should now treat their patients."
Six months of oxaliplatin-based chemotherapy has been the standard adjuvant therapy for stage III colon cancer since 2004. However, the neurotoxicity of oxaliplatin sparked research into whether three months of therapy provided the same benefit but with reduced side effects.
Six randomised phase III trials have been conducted worldwide comparing three versus six months of chemotherapy with FOLFOX or CAPOX. The IDEA study was a pooled analysis of the 12,834 patients enrolled in the six trials. It showed that six months gave less than 1% added benefit over three months when all patients and both types of chemotherapy were included in the analysis.
Investigators of the four most mature trials (SCOT, TOSCA, ACHIEVE, IDEA-FRANCE) will present their results during the congress session. Expert interpretation will be given by a clinician and a statistician. Gastrointestinal cancer specialist Professor Andrés Cervantes, Chair of the ESMO Educational Committee, member of the ESMO Guidelines Committee and session co-chair, will discuss how the latest data in this debate will practically impact the ESMO Clinical Practice Guidelines on Early Colon Cancer, which are set to be updated in 2018. Members of the panel will be asked to vote for three or six months of treatment in a variety of clinical scenarios.
Distinguished panel for the Special Session:
- Andrés Cervantes, session co-chair and Chair of ESMO Educational Committee. Medical Oncology Department, INCLIVA University of Valencia, Valencia, Spain.+*
- Alberto Sobrero, session and ESMO 2017 congress co-chair. Medical Oncology Unit, IRCCS San Martino, Genova, Italy.*
- Marc Buyse, Associate Professor of Biostatistics, Universiteit Hasselt, Belgium and Associate Editor, Annals of Oncology (Statistics).
- Axel Grothey, Division of Medical Oncology, Mayo Clinic, Rochester, MN, US.*
- Timothy Iveson, Department of Medical Oncology, University Hospital Southampton, Southampton, UK.
- Roberto Labianca, Cancer Centre, Ospedale Giovanni XXIII, Bergamo, Italy.+*
- Tim Maughan, Oxford Institute for Radiation Oncology, Professor of Clinical Oncology, University of Oxford, Oxford, UK.*
- Jeffrey A. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, US.
- Anthony F. Shields, Professor of Medicine and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, US.
- Ioannis Souglakos, Assistant Professor of Medical Oncology, Medical School, University of Crete, Medical Oncologist, University Hospital of Heraklion, Greece.
- Julien Taieb, Head of the Gastroenterology and GI Oncology Department, Georges Pompidou European Hospital, Paris Descartes University, France.*
- Takayuki Yoshino, National Cancer Centre Hospital East in Chiba, Japan.*
"The common sense conclusion from the IDEA study is that it's not worth going through the toxicity and inconvenience of six months to gain less than 1% efficacy," said Sobrero. "Especially considering that the toxicity is cut by at least 50% with the three month regimen."
"Statistically, three months of treatment was slightly inferior to six months in the overall study population of stage III patients," added ESMO spokesperson Professor Eric Van Cutsem, main author of the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Head of Digestive Oncology, University Hospitals Leuven, Belgium. "However, the clinical conclusion, given the reduction in neurotoxicity with a shorter duration of treatment, was that three months is almost identical to six months."
Two additional analyses revealed unexpected findings. First, for high risk stage III patients (N2 or T4) the difference in efficacy widens in favour of six months. Second, the results differ according to the type of chemotherapy. CAPOX is equally effective at three or six months, independently of the patient's level of risk. Six months of FOLFOX is more effective than three months.
Sobrero said: "While overall there are minor differences in efficacy between three and six months, high risk patients should receive six months of chemotherapy and CAPOX should be preferred over FOLFOX."
"In low risk patients the difference was so minor that the clinical conclusion is that three months of oxaliplatin-based chemotherapy is as good as six months," said Van Cutsem. "Although statistically the difference is small, this makes a huge clinical difference to patients with the reduction in neurotoxicity."
Regarding the standard of care for adjuvant chemotherapy in stage III colon cancer, Van Cutsem said: "In high risk patients six months remains the standard, but in low risk patients three months should become the new standard duration of treatment."
Van Cutsem confirmed that this is the strategy he uses with his stage III colon cancer patients. He said: "In high risk stage III patients we give six months of FOLFOX - unless the patient has neurotoxicity, in which case we stop oxaliplatin but continue with 5FU for a total duration of six months. In patients with low risk tumours, we give three months of FOLFOX."
Sobrero said most patients prefer the three month option which gives much lower toxicity for very little loss in efficacy. He said: "Every now and then I see a patient who does not want to lose even 1% of efficacy and wants six months of chemotherapy. This is just one of the fascinating aspects of implementing the data from the IDEA study. We will thoroughly debate the issues and give clear conclusions during this session, which is set to be packed with health professionals who face patients with this serious disease everyday and desperately want better treatments."
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO 2017 Congress
+Co-author of ESMO Clinical Practice Guidelines on Early Colon Cancer.
*Co-author of ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer.
1 The following abstracts will be presented during Special Session 'When clinical practice demands to go beyond statistics: Adjuvant chemotherapy of colon cancer. The 3 vs 6 month story' on Monday, 11 September 2017, 14:45 to 16:15 (CEST) in Madrid Auditorium.
LBA21_PR 'Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)' will be presented by Axel Grothey.
LBA22 'Updated results of the SCOT study: An International Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer' will be presented by Timothy Iveson.
LBA23 'FOLFOX4/XELOX in stage II-III colon cancer: efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial' will be presented by Roberto Labianca.
LBA24 'Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration' will be presented by Takayuki Yoshino.
473O 'Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: per-protocol, subgroups and long-lasting neuropathy results' will be presented by Julien Taieb.
Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct .
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.